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Background
At present, we do not have any biological tests which can
contribute towards a diagnosis of depression. Neuroimaging
measures have shown some potential as biomarkers for
diagnosis. However, participants have generally been from the
same ethnic background while the applicability of a biomarker
would require replication in individuals of diverse ethnicities.
Aims
We sought to examine the diagnostic potential of the structural
neuroanatomy of depression in a sample of a wide ethnic diversity.
Method
Structural magnetic resonance imaging (MRI) scans were
obtained from 23 patients with major depressive disorder in
an acute depressive episode (mean age: 39.8 years) and
20 matched healthy volunteers (mean age: 38.8 years).
Participants were of Asian, African and Caucasian ethnicity
recruited from the general community.
Results
Structural neuroanatomy combining white and grey matter
distinguished patients from controls at the highest accuracy of
81% with the most stable pattern being at around 70%. A
widespread network encompassing frontal, parietal, occipital
and cerebellar regions contributed towards diagnostic
classification.
Conclusions
These findings provide an important step in the
development of potential neuroimaging-based tools for
diagnosis as they demonstrate that the identification of
depression is feasible within a multi-ethnic group from the
community.
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Major depressive disorder (MDD) is characterised by a persistently
low mood and an inability to experience pleasure that is accom‐
panied by disturbances in neurovegetative symptoms, in particular
in sleep and appetite, impairments in cognitive functioning, and
often feelings of guilt and suicidal ideation of varying intensity.1
The diagnosis is made on the basis of clinical signs and symptoms
from an assessment with the individual and additional informa-
tion when available. However, at present, there are no biological
measures which are diagnostic for depression or for any psychia-
tric disorder.
Findings from neuroimaging research though offer the
potential to develop biomarkers which could aid in the diagnosis
of depression.2 Structural neuroimaging studies of depression have
revealed widespread cortico-limbic deficits in grey matter (GM)3
as well as in white matter (WM).4 Moreover, regional atrophy in
the hippocampus may already be present in the first episode of
depression5 and may worsen with recurrent episodes, in particular
in patients with a more treatment-resistant form of depression.6
Similarly, alterations in WM integrity5 have been observed in the
first episode7 and in adolescents at familial risk.8
A number of studies have examined how well structural
magnetic resonance imaging (MRI) data are able to diagnose
depression. Structural MRI scans are non-invasive, may be readily
acquired, and are generally well tolerated as they are relatively
short scans and do not require participants to perform a specific
task while in the scanner, providing an accessibility which is
important for a potential biomarker.9 Using structural MRI scans,
the accuracy of diagnosis for depression has ranged from 48% to
91% (Table 1).10–16 We would not expect to achieve a perfect
accuracy with current diagnostic criteria that are based on clinical
signs and symptoms which are not necessarily linked to aetiology.17
Rather we would expect that there would be an iterative process
by which the factors contributing to the neuroimaging classifica-
tion would be delineated and the classification findings would in
turn lead to new hypotheses.18
Factors which contribute to the accuracy of the generated
classification include the subtype of depression examined, features
of the brain imaging measure which were included, and the
method of analysis. Some of the highest accuracies have been
achieved in patients with a well-recognised and more treatment-
resistant form of depression11,13 who were taking a number of
medications.13 The identification of depression seems to show an
improved accuracy with the inclusion of WM rather than that
from GM alone,11,12 and neuroimaging analysis methods which
bring together measures from a number of regions are better able
to detect widespread, subtle anatomical changes.2,19 However,
studies to date had included individuals who were predomi‐
nantly from the same ethnicity: Caucasian10,13 and Chinese.11,12,16
Ethnicity is moderating factor for functional brain responses in
healthy participants,20 while an effect on structural neural features
may be more mixed with evidence of differences in cortical
thickness in frontal and parietal regions21 but not in hippocampal
asymmetry.22 Ethnicity could thus impact on potential functional
MRI-based markers while structural MRI-based markers may be
more robust.
In the present study, we sought to examine how well structural
MRI scans would identify patients with the form of depression
that is most commonly observed in the community in an
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ethnically diverse sample of Asian, African and Caucasian descent,
who were suffering from either their first or a recurrent form of
depression and were all medication-free. We applied a multi-
variate imaging pattern analysis method which integrates regi‐
onal cerebral data, namely optimally discriminative voxel-based
analysis,23,24 and we examined the accuracy of diagnosis based on
GM, WM and their combination using a support vector machine
(SVM) method.25 We expected that GM would demonstrate a
high diagnostic accuracy for depression and that an even higher
accuracy may be achieved with WM in the multi-ethnic sample.
Method
Study design and participants
This is an open-label study which was approved by the
Cambridgeshire 4 Research Ethics Committee. Patients were
recruited from the local community by newspaper advertisements,
and all participants provided informed written consent. The study
was conducted in conformity with the Declaration of Helsinki and
its amendments.
Participants were patients with MDD (n=23) and healthy
controls (n=20), right-handed and matched for age, gender and IQ
(all P>0.3) (Table 2). A diagnosis of MDD, single or repeated
episode MDD without psychotic features, was made as defined by
Diagnostic Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision26 and assessed with the Structured Clinical Inter-
view for DSM-IV Axis I Disorders (SCID-IV)27 without any
comorbid disorders. All patients had a minimum score of 18 on
the 17-item Hamilton Depression Rating Scale (HAMD)28 at the
time of study entry and were free of antidepressant medication for
a minimum of 4 weeks before the start of the study (or 6 weeks for
fluoxetine). Healthy controls had no history of psychiatric
disorders, interviewed with SCID-IV,27 and had an HAMD score
of ≤7. MRI scans were acquired at baseline (week 0) and at weeks
1, 8 and 12. MDD patients received treatment with an anti-
depressant medication following the baseline assessment.29
The present study focuses on the baseline data while MDD
patients were in an acute depressive episode. Baseline MRI scans
were obtained from 29 MDD patients and 22 healthy controls.
Data from two healthy volunteers had to be excluded due to
excessive movement during the structural MRI scan. The present
Ta
b
le
1
(C
on
tin
ue
d)
H
ea
lth
y
co
nt
ro
ls
Pa
tie
nt
s
P
St
ud
y,
ye
ar
M
RI
N
(m
al
es
)
A
ge
,
ye
ar
s
(s
.d
.)
N
(m
al
es
)
A
ge
,
ye
ar
s
(s
.d
.)
D
ia
gn
os
is
M
ed
ic
at
io
n
C
om
pa
ris
on
C
la
ss
ifi
er
Fe
at
ur
e
A
cc
ur
ac
y
Se
ns
iti
vi
ty
Sp
ec
ifi
ci
ty
Su
lc
al
de
pt
h
58
56
59
0.
12
Ja
co
bi
an
M
et
ric
D
is
to
rt
io
n
67
63
72
0.
00
2
+
+
+
C
om
bi
na
tio
n
pa
ra
m
et
re
s
69
69
69
0.
00
2
M
ed
,M
ed
ic
at
io
n;
H
A
M
D
,1
7-
ite
m
H
am
ilt
on
D
ep
re
ss
io
n
Ra
tin
g
Sc
al
e;
M
D
D
,m
aj
or
de
pr
es
si
ve
di
so
rd
er
;T
RD
,t
re
at
m
en
t-
re
si
st
an
t
de
pr
es
si
on
;p
M
D
D
,p
sy
ch
ot
ic
M
D
D
;H
V,
he
al
th
y
vo
lu
nt
ee
rs
;G
M
,g
re
y
m
at
te
r;
W
M
,w
hi
te
m
at
te
r;
C
SF
,c
er
eb
ro
sp
in
al
flu
id
;S
VM
,s
up
po
rt
ve
ct
or
m
ac
hi
ne
s;
PC
A
,
pr
in
ci
pl
e
co
m
po
ne
nt
an
al
ys
is
;
RF
E,
re
cu
rs
iv
e
fe
at
ur
e
el
im
in
at
io
n;
LL
E,
lo
ca
lly
lin
ea
r
em
be
dd
in
g;
VB
M
,
vo
xe
lb
as
ed
m
or
ph
om
et
ry
;
RV
M
,
re
le
va
nc
e
ve
ct
or
m
ac
hi
ne
;
FB
M
,
fe
at
ur
e
ba
se
d
m
or
ph
om
et
ry
;
EM
,
ex
pe
ct
at
io
n-
m
ax
im
is
at
io
n
du
st
er
in
g
al
go
rit
hm
;
KM
ea
ns
,s
im
pl
e
K
m
ea
ns
cl
as
si
fic
at
io
n
vi
a
cl
us
te
rin
g;
TU
D
,t
re
at
m
en
t
un
re
sp
on
si
ve
pa
tie
nt
s.
D
ep
re
ss
io
n
st
at
us
of
M
D
D
pa
tie
nt
s:
fir
st
-e
pi
so
de
–
Li
u
(2
01
2)
,Q
iu
(2
01
4)
,S
er
pa
(2
01
4)
;f
irs
t-
ep
is
od
e
an
d
re
cu
rr
en
t
–
C
os
ta
fr
ed
a
(2
00
9)
;r
ec
ur
re
nt
:M
w
an
gi
(2
01
2)
;n
ot
st
at
ed
:G
on
g
(2
01
1)
,K
ip
li
(2
01
3)
.
a.
So
m
e
of
th
e
pa
tie
nt
s
w
er
e
m
ed
ic
at
io
n
fr
ee
.
b.
χ2
P.
c.
31
-it
em
H
A
M
D
.
+
M
w
an
gi
(2
01
2)
:d
at
a
w
er
e
ra
nd
om
ly
di
vi
de
d
in
to
tw
o
se
ts
(tr
ai
ni
ng
se
t,
te
st
in
g
se
t)
of
eq
ua
ln
um
be
r
of
pa
tie
nt
s
an
d
co
nt
ro
ls
(n
=
31
).
In
pa
tie
nt
s,
de
pr
es
si
on
w
as
co
ns
id
er
ed
to
be
tr
ea
tm
en
t
un
re
sp
on
si
ve
.M
in
im
um
du
ra
tio
n
of
ill
ne
ss
w
as
>
3
m
on
th
s
w
ith
an
tid
ep
re
ss
an
t
m
ed
ic
at
io
n.
+
+
Ki
pl
i(
20
13
),
ac
cu
ra
cy
of
82
.3
%
al
so
ob
ta
in
ed
w
ith
ot
he
r
cl
as
si
fie
rs
:i
nf
or
m
at
io
n
ga
in
:-J
48
,
in
fo
rm
at
io
n
ga
in
-R
an
do
m
Fo
re
st
,
SV
M
-K
M
ea
ns
,S
VM
-R
an
do
m
Fo
re
st
,R
el
ie
fF
-R
an
do
m
Tr
ee
,a
ll-
na
ïv
e
ba
ye
s.
+
+
+
C
om
bi
ne
d
pa
ra
m
et
er
s:
Q
iu
(2
01
4)
in
te
gr
at
ed
al
lt
he
m
or
ph
om
et
ric
pa
ra
m
et
er
s
(i.
e.
co
rt
ic
al
th
ic
kn
es
s,
vo
lu
m
e,
pl
ia
la
re
a,
cu
rv
at
ur
e
ar
ea
,s
ul
ca
ld
ep
th
an
d
Ja
co
bi
an
m
et
ric
di
st
or
tio
n)
of
th
e
le
ft
an
d
rig
ht
he
m
is
ph
er
es
w
ith
in
a
si
ng
le
m
od
el
to
in
ve
st
ig
at
e
th
e
di
sc
rim
in
at
iv
e
po
w
er
of
th
e
re
su
lti
ng
co
m
bi
na
tio
n.
Table 2 Demographic and clinical characteristics
MDD patients Healthy controls P
Participants, n 23 20
Age, years: mean (s.d.) 39.8 (11.2) 38.8 (9.9) 0.84
Male, n (%) 13 (56.5) 12 (60.0) 0.82
Ethnicity, n (%)
Asian 8 (34.8%) 3 (15.0%)
Black/African American 2 (8.7%) 5 (25.0%)
Caucasian 13 (56.5%) 12 (60.0%)
Baseline scores,a mean (s.d.)
HAMD 22.0 (2.9) 0.5 (1.1) <0.001
HAMA 20.7 (5.4) n/a
Week 12 scores,a mean (s.d.)
HAMD 6.9 (4.6) 0.6 (1.3) <0.001
HAMA 7.5 (4.4) 0.6 (1.1) <0.001
Full IQ 107.8 (10.7) 109.2 (14.6) 0.63
Performance IQ 103.2 (14.4) 107.9 (15.2) 0.3
Verbal IQ 110.0 (9.9) 109.8 (12.4) 0.95
HAMA, Hamilton Scale for Anxiety; HAMD, 17-item Hamilton Rating for Depression;
MDD, major depressive disorder; n/a, not assessed.
a. Ratings were acquired at baseline, during an acute depressive episode and
following 12 weeks of treatment for patients, and at baseline and at the 12-week
follow-up for healthy participants.
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Pattern classification in depression
study consists of those participants who had completed all the
scans in the study: 23 MDD and 20 healthy controls, as the SVM
analysis requires approximately equal numbers of participants.
Data acquisition
Structural MRI scans were acquired on a 3-T GE SIGNA HDx
(Milwaukee, USA) at King’s College London. A structural image
was acquired at each session: Magnetisation Prepared Gradient
Echo, resolution 1 mm3, acquisition parameters: echo time (TE):
2.85 ms, reaction time (TR): 6.98 ms, flip angle: 8°, slice thickness:
1.2 mm, interslice gap: 1.2 mm, field of view: 260 mm, matrix
size: 6464.
Image preprocessing
Preprocessing of the structural MRI T1 weighted images included
bias correction, skull stripping and tissue segmentation. Bias
correction was performed using N41TK, which is an improved
MNI_N3 bias correction software package available at http://www.
insight-journal.org/browse/publication/640package. Skull strip-
ping was completed using Multi-Atlas Skull Stripping software
(MASS, version 1.0), which is based on a multi-atlas registration
framework and uses a set of templates from the study data set
which best represents the anatomical variations.30 The images
were then segmented into GM, WM and cerebrospinal fluid (CSF)
using the automated algorithm Multiplicative Intrinsic Compo-
nent Optimization (MICO).31 The quality of the processed images
was ensured by automated quality control measures and manual
review.
Spatial registration of all the skull-stripped images to the Jakob
template was performed using the Deformable Registration via
Attribute Matching and Mutual-saliencing Matching registration
package (DRAMMS, version 1.1.0; http://www.cbica.upenn.edu/
sbia/software/dramms/index.html).32 The deformation field from
the resulting registration was used to obtain the Regional Analysis
of Volumes Examined in Normalized Space (RAVENS) maps or
regional volumetric maps for GM, WM and CSF. The maps were
corrected for individual intracranial volume, down-sampled to
222 mm3.
Analysis of structural neuroanatomy: GM and WM
Regional differences in GM and WM between MDD patients
and healthy controls were performed with the Optimally Dis-
criminative Voxel Based Analysis (ODVBA, version 2.0) software
package23 using the RAVENS maps. In ODVBA, the regional dis‐
criminative analysis which is restricted by the non-negativity
constraints is firstly applied to a spatial neighbourhood around
each voxel in order to identify the coefficients that best highlight
the differences between two groups in that neighbourhood.
Secondly, the statistical value of each voxel is then determined
by a composition of contributions from all neighbourhoods to
which it belongs. Finally, the statistical significances are obtained
by using permutation tests. In the present study, 2000 permuta-
tions were used to derive the significances, and significance was
assigned as P (uncorrected)<0.001 because of the relatively small
sample size. ODVBA has shown greater sensitivity to detect subtle
structural abnormities and improved delineation of the region of
abnormality as compared with conventional GLM methods23,24 in
various clinical studies.33,34
Classification using SVM
The GM and WM RAVENS maps were concatenated into a single
feature vector for each participant. Classification was performed
using SVM,35 a multivariate classification technique that can
optimally use high dimensional information such as neuroimaging
data.10,19 SVM identifies the optimal linear decision boundary, or
hyperplane, that has the maximum margin separating the two
training groups, namely MDD patients and healthy controls. SVM
treats individual images as points located in high dimensional
space. In SVM, both the hyperplane as well as the margin are
important in classification accuracy, and usually the wider the
margin the better the classification accuracy.35
SVM also extracts weight vectors as images, known as SVM
discrimination maps, which represent the direction in which
the two groups differ the most, and the significance levels were
determined using analytical permutation testing.25 We used an
advanced version which accounted for the SVM margins in
addition to the SVM weights.36 The SVM analysis was performed
using fivefold cross-validation strategy. The classification scores
derived from the SVM analysis was evaluated using a receiver
operating characteristic (ROC) curve to illustrate the diagnostic
accuracy of the classifier. The area under the curve (AUC) was
calculated from the ROC curve, which is a measure of the
discriminative power of the classifier and is independent of the
chosen P value or sample size.
The GM and WM RAVENS maps were also analysed using
the SVM-based classification technique Classification of Morpho-
logical Patterns using Adaptive Regional Elements (COMPARE).37
The first step in this method is feature selection wherein regions
that show high correlation between RAVENS maps and partici-
pant groups are extracted using a watershed algorithm. A further
volume-increment algorithm is then applied to these regions to
extract regional volumetric features, from which a feature selection
method based on SVM classification criteria is used to identify
the most relevant features for classification.37 The feature selection
procedure produces a small number of volumetric measurements
for more effective classification. The SVM classification technique
with the most distinguishing features is then used to predict group
differences using the leave-one-out cross-validation strategy.37
Results
Structural neuroanatomy
In GM density, reductions were revealed in the right superior
frontal region (Talairach coordinates: x, y, z: 17.8, 31.5, 48.2; mass
size: 74 voxels), right superior medial frontal region (x, y, z: 11.9,
31.7, 51.8; mass size: 14 voxels) and superior temporal regions
(x, y, z: 53.5, 43.6, 20.6; mass size: 13 voxels) in MDD patients
compared with healthy controls (P<0.001, uncorrected), and in
WM density, reductions were evident in the right postcentral (x, y,
z: 25.7,41.8, 57.4; mass size: 14 voxels), superior parietal (x, y, z:
21.8,57.3, 58.1; mass size: 212 voxels), middle temporal (x, y, z:
49.5, 51.6, 17.3; mass size: 46 voxels) and left inferior occipital
regions (x, y, z: 37.6, 75.8, 1.3; mass size: 10 voxels) in
MDD patients relative to healthy controls (P<0.001, uncorrected)
(Fig. 1). There were no regions which showed greater volume in
MDD patients relative to controls.
Diagnostic classification
Using SVM analysis, 78.3% of MDD patients (sensitivity: 18 of 23
patients) and 55.0% of healthy controls (specificity: 11 of 20
healthy controls) for an overall accuracy of 67.4% (AUC=0.73,
P=0.02, positive predictive value=66.67%, negative predictive
value=68.75%) were correctly classified based on the combination
of GM and WM density (Fig. 2). Based on GM only, the accuracy
was reduced to 60.5%, which did not reach statistical significance
(AUC=0.55, P=0.2), while the accuracy was higher at 65.1%
(AUC=0.73, P=0.05) based on WM only. Regions which con-
tributed to the classification of MDD patients included WM
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regions in the superior and medial frontal gyri, superior parietal
and inferior occipital gyri, and in the cerebellum (Fig. 2).
From the COMPARE analysis which included feature selec-
tion, the highest classification rate was 81.4% based on 47 features,
while the most stable pattern was observed with an accuracy of
around 70% based on 50–70 features (Fig. 2).
Discussion
At present, the diagnosis of depression is based solely on clinical
signs and symptoms, and there are no biological markers that can
identify the disorder or predict clinical response. Using structural
neuroimaging measures and machine-learning analysis, we have
identified a potential non-invasive biomarker which can aid in
the diagnosis of MDD in patients from a wide ethnic diversity
from a community sample. Moreover, the features of depression
which are commonly observed in the community were reflected in
the present group as all the patients were in an acute depressive
episode, were not taking any medications, and were suffering from
some degree of psychosocial impairments. These findings provide
an important step in the development of potential neuroimaging-
based tools for clinical diagnosis as the findings demonstrate that
the identification of depression is feasible within a multi-ethnic
group from the general community.
It was notable that the highest accuracy was achieved from
combining GM and WM features in the structural MRI scans.
Regions which contributed to classification included a widespread
network encompassing the superior and medial frontal, superior
parietal and inferior occipital regions. MDD patients showed
GM atrophy in the right superior frontal and temporal regions as
well as loss of WM density in the parietal, inferior occipital and
lateral temporal regions compared with the healthy controls.
Deficits in GM have been consistently reported in the prefrontal
regions extending into the precentral cortex and subcortically into
the thalamus.3
Abnormalities in WM have been observed as reductions
in volume as well as in fractional anisotropy, a measure of
connectivity that is derived from diffusion tensor imaging, also
extending from frontal to parietal and occipito-temporal regions,38
which may be associated with more severe symptoms.4 A higher
accuracy of diagnosis has been reported in patients with a greater
severity of illness and of the same ethnicity.11,12 Similar regions
had contributed to the diagnosis, namely WM regions in the
frontal, parietal, and occipital lobes.11,12 We also found that WM
regions in the bilateral cerebellum contributed towards diagnostic
classification, which has been previously observed12 but more
frequently has not been examined.14–16 The cerebellum is involved
in the regulation of emotional responses,39 and GM40 as well as
WM41 deficits have been reported in depression. These findings
underline the wide distribution of GM and WM abnormalities
within fronto-limbic networks in depression, supporting the nec‐
essity of analyses which are capable of combining these features,
rather than examining each region individually.
Ethnicity has a significant impact on the development and
prognosis of psychiatric and neurological disorders, which may be
reflected in their neuropathology.42 Perceived discrimination has
been associated with greater activation and increased connectivity
with the anterior cingulate cortex in healthy participants from an
ethnic minority which was in part mediated by chronic stress.20
Effects on structural neuroanatomy may be more mixed as
no significant effects were observed of ethnicity on hippocampal
asymmetry in a community sample22 or on structural brain
volumes when young Chinese Singaporeans were compared with
White Americans,21 although differences in cortical thickness
were reported as young White Americans had greater thickness in
frontal and right superior parietal regions compared with
Singaporeans, who in turn showed increased thickness in the
left inferior temporal gyrus.21 Moreover, a comparison of hemi-
spheric shape between Eastern and Western populations revealed
shorter but wider hemispheres for Japanese relative to European
participants.43 In multiple sclerosis, greater T1-weighted lesion
(a) (b)
P<0.001
Trends towards significance
0 10
Fig. 1 Map of regions which showed a signiﬁcant difference in grey and white matter in MDD patients and healthy controls: (a) grey matter regions
demonstrating atrophy in MDD patients relative to healthy controls, (b) white matter regions demonstrating atrophy in MDD patients relative to
healthy controls. Green indicates signiﬁcant regions at P<0.001 uncorrected, and areas of red colour (threshold P<0.05) indicates the trend towards
signiﬁcance characterised by –log(p) values as shown in the colour bar.
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volumes have been reported in patients of African compared with
Caucasian ethnicity.44 Our present findings indicate potential
reproducibility in the structural neuroanatomy in depression from
diverse ethnicities.
Structural neuroimaging has also demonstrated a comparable
accuracy for the diagnosis of schizophrenia, revealing an accuracy
of 78% from a meta-analysis in comparison with healthy controls.45
In the present study, we achieved an accuracy of 81%, although the
most stable findings were at an accuracy of around 70%. We would
expect a higher accuracy for the diagnosis of schizophrenia, which
is associated with greater global brain volume reductions, extensive
regional atrophy as well as WM disruptions.46 Furthermore, we
would not expect to fully replicate current diagnostic criteria
systems. The process of developing potential neuroimaging-
based biomarkers would involve an iterative process, in which the
findings would lead to new hypotheses and would be incorporated
as prior knowledge for subsequent studies.18
The majority of machine-learning analyses of neuroimaging
measures in depression have examined the predictive potential of
structural neuroanatomy and functional neural correlates for
diagnosis and prognosis using SVMs.18 Major advantages of
structural MRI measures is the ease with which the data can be
acquired, its reliability and reproducibility, as well as its accept-
ability by patients. While we would not expect that neuroimaging-
based diagnostic classification would wholly reproduce current
symptom-based classifications, we would emphasise the need for
biological markers to aid in the diagnosis of depression and other
psychiatric disorders. This would be of particular importance
for patients who may not be able to participate in the clinical
assessment, who are unable to provide a sufficient clinical history,
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Fig. 2 (a) Schematic map showing white matter regions which contributed towards diagnostic classiﬁcation of MDD, regions are presented at
P<0.05 uncorrected. Blue indicates regions showing atrophy in MDD patients relative to controls and yellow indicates regions of greater volume in
MDD patients compared with healthy controls. (b) Receiver operating characterstic (ROC) curve for the comparison between MDD and healthy
participants, area under curve (AUC)=0.73, P=0.02. The x-axis is the false positive rate (1-speciﬁcity) and the y-axis is the true positive rate
(sensitivity). (c) Graph illustrating change in classiﬁcation rate with number of attributes selected. The x-axis indicates the number of attributes and
the y-axis the classiﬁcation rate. The highest classiﬁcation rate was 81.4% based on 47 features, while the most stable pattern was observed with an
accuracy of around 70% based on 50–70 features.
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or when the specific diagnosis is unclear. Examining a single
neuroimaging measure though may not fully encompass the
multitudinous aspects of the disorder’s complex psychopathology.
Moreover, the specificity of the diagnostic classification could
have implications for healthy individuals. We would expect that
the specificity of the classification would improve in an itera‐
tive process in the development of the potential biomarker.18
However, if the specificity were to remain low, this would have
implications for the clinical applicability of the biomarker as
well as for those healthy individuals who have structural neural
features that are comparable with individuals with a diagnosis of
depression, analogous to having genetic polymorphisms that are
associated with increased risk for the development of a particular
disorder or malignancy. Future longitudinal studies are needed to
clarify the accuracy of diagnosis and could likely benefit from
examining multiple neuroimaging measures as well as different
machine-learning techniques. The challenge is to look for valid
biomarkers of symptom conditions, perhaps incorporating neural
and genetic measures. Such biomarkers could aid clinical inter-
views and decisions regarding diagnosis, prognosis and disease
progression.
A limitation of the present study is the relatively small sample
size, although comparable to previous studies.11–13 In order to
develop a diagnostically meaningful tool, it is essential to ensure
unbiased testing of the model. Ideally, the model should be tested
in an independent sample of patients with MDD to evaluate
and to validate the generalisability of the model. However, a
significant challenge of the analysis of data sets from different
scanners is the systematic difference in the scanner protocols and
the acquired images, and an important step in the analysis would
be to harmonise the data from the different scanners. In the
present study, we applied a fivefold cross-validation strategy, by
which the whole data set was randomly divided into five exclusive
subsets of equal size, and for each fold one of these subsets was
used as a test set, while the remaining four were used as training
data sets. Furthermore, this process was repeated a thousand times
with randomly permuted class labels in order to determine the
significance of the classification accuracy. As we achieved conver-
ging results from both an SVM model on the imaging data and the
COMPARE high-dimensional feature extraction and classification
method, and we applied proper cross-validation in the analysis, we
believe that our models provide unbiased and robust findings.
Advantages of the current sample include that all patients were
medication-free status while in an acute depressive episode and
were recruited from the community, as one of the highest clas‐
sification accuracy was observed in patients who were already
on antidepressant medications;13 patients were in their first
episode11,16 as well as having a history of recurrent episodes;10
and there was wide ethnicity which included Asian, African and
Caucasian participants. Another concern is the access and cost of
the MRI scan and the computational requirements of the analysis.
We would envisage a database and analysis centre which the data
could be sent to and the centre would provide a measure of the
likelihood of the diagnosis, as well as the prognosis, and would
form part of the clinical assessment and management.
In summary, we found that the diagnosis of MDD is feasible
to a high level of accuracy in patients from a wide ethnic diversity.
Diagnosis was based on a widespread network of WM as well
as GM. The identification of individual patients with depression
from an ethnically diverse, community sample indicates the gen‐
eralisability of the diagnostic neural pattern and provides a
valuable step in the development of diagnostic biomarkers.
Multicentre validation studies would be important to test the
robustness of the present findings.
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